Median progression-free survival was 26 months ( 95 % CI 19-28 ) in both the dacomitinib group and the erlotinib group ( stratified hazard ratio [ HR ] 0941 , 95 % CI 0802-1104 , one-sided log-rank p = 0229 ) .